The Disease Interception Accelerator and Janssen Pharmaceuticals, Inc. entered into a research agreement with Washington University and award-winning immunologist Emil Unanue, M.D., Paul & Ellen Lacy Professor of Pathology & Immunology at Washington University, to identify the root cause of type 1 diabetes and enable the development of interventions that halt progression to disease.